Abstract | BACKGROUND: The aim of this study was to investigate the impact of anti-HBc (HBcAb) positivity on the progression of liver fibrosis ( Fibrosis-4 score >3.25) in the Italian cohort of HIV-infected individuals naïve to antiretroviral treatment (ICONA). METHODS: All patients with FIB-4 <3.25 at baseline were evaluated prospectively: 6966 people with HIV (PWH) were screened and classified based on hepatitis B virus (HBV) and hepatitis C virus (HCV) serology. RESULTS: Patients who were HBcAb+/HCV-/HBs antigen ( HBsAg)- and HCV+/HBcAb+/ HBsAg- or HBsAg+/HBcAb+/HCV- had CD4+ cell counts below the nadir and significantly higher prevalence of AIDS diagnosis at baseline than the other groups (P < .0001). A Cox regression model adjusted for age, HIV transmission mode, country of birth, and alcohol consumption showed a higher relative risk (HR) of progression to FIB-4 >3.25 in HCV+/HBcAb+/ HBsAg- patients (HR, 7.2; 95% CI, 3 8-13.64). CONCLUSIONS: HBcAb+ contributes to liver damage in HIV+/HCV+/HBcAb+/ HBsAg- subjects. A careful monitoring for signs of previous HBV infection is needed in this kind of patients.
|
Authors | Vincenzo Malagnino, Carlotta Cerva, Antonella Cingolani, Francesca Ceccherini-Silberstein, Alessandra Vergori, Gianluca Cuomo, Carlo Federico Perno, Massimo Puoti, Antonella d'Arminio Monforte, Alessandro Cozzi-Lepri, Massimo Andreoni, Loredana Sarmati, ICONA Foundation Study Group |
Journal | Open forum infectious diseases
(Open Forum Infect Dis)
Vol. 8
Issue 1
Pg. ofaa566
(Jan 2021)
ISSN: 2328-8957 [Print] United States |
PMID | 33447635
(Publication Type: Journal Article)
|
Copyright | © The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America. |